Washington—Combining checkpoint inhibitors yields an overall survival (OS) benefit in advanced melanoma, according to Phase III data presented at the 2017 annual meeting of the American Association for Cancer Research (AACR). Two other studies in advanced melanoma presented at the AACR meeting also generated favorable results when a checkpoint inhibitor was combined with something else.
Nivolumab Plus Ipilimumab
In the randomized Phase III trial, the combination of